Tumour uptake of 57-cobalt-bleomycin in patients with breast cancer

L. Pace, G. D'Aiuto, C. Acampora, P. Oliviero, G. Botti, F. Tatangelo, M. Cerra, M. Salvatore

Research output: Contribution to journalArticlepeer-review


17 patients with breast carcinoma were studied with 57-cobalt-bleomycin scintigraphy. Scans showed increased tumour uptake in all patients. Results expressed as percentage of the injected dose (ID) normalised by the size of the tumour region (% ID/pixel) showed higher tumour uptake in patients with T3-T4 breast carcinomas (n = 5) than in patients with T1-T2 breast cancer (n = 12) (8.4 ± 0.55 × 10-3 vs. 5.25 ± 1.71 × 10-3 % ID/pixel, respectively, P <0.05). An inverse correlation between tumour uptake of 57-cobalt-bleomycin and progesterone receptor concentration was also found in all tumours tested (r = -0.60, P <0.05, n = 10) and was confirmed in the group of patients with T2 breast carcinomas (r = -0.89, P <0.05, n = 6). We conclude that a quantitative analysis of 57-cobalt-bleomycin uptake can give additional information suitable for the presurgical characterisation of a tumour.

Original languageEnglish
Pages (from-to)195-198
Number of pages4
JournalEuropean Journal of Cancer
Issue number2
Publication statusPublished - 1993

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology


Dive into the research topics of 'Tumour uptake of 57-cobalt-bleomycin in patients with breast cancer'. Together they form a unique fingerprint.

Cite this